Developing the next generation of nerve agent antidotes. The first therapeutic capability was designed to preserve both life and brain function.
VIEW THE MISSION ↓Nerve agents—including Sarin, VX, and Novichok—remain a credible and evolving threat in asymmetric conflicts. Current medical countermeasures (legacy oximes) save lives; they were designed for survival, not neuroprotection.
"Current countermeasures keep the victim alive but leave them unprotected from longterm neurologic injury."
Legacy solutions cannot reach the brain effectively to stop central seizure activity.
The first nerve-agent antidote capable of crossing the blood-brain barrier to preserve neurologic function.
Developed at Lawrence Livermore National Laboratory (LLNL), LLNL-02 / CX-101 is engineered to replace the 60-year-old agent currently in the Strategic National Stockpile.
Developed by LLNL research scientists as the first nerve-agent antidote capable of crossing the blood-brain barrier.
Demonstrates approximately 5x longer durable systemic exposure than current standard-of-care antidotes.
Designed as a superior replacement for legacy oximes in existing autoinjector platforms—not just an adjunct.
A mandated execution program aligned with national security requirements.
Non-Dilutive Gov Investment
Developed at Lawrence Livermore National Lab
Animal Rule Pathway (No Human Efficacy Trials)
Guaranteed Buyer & Validator
Expertise: Program execution & leadership.
20 + years of global development & regulatory expertise.
25+ years in CMC, scale-up, and GMP readiness.
26-year pharma leader & US Marine.